Developer docs
API playgroundTry for free, no card

Search company profiles

UBT Srl

Full company profile

uuid000ujpn

Namestring
UBT Srl
Legal namestring
UBT Srl
Websiteurl
ubt-tech.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

UBT Srl is an Italian medical device company that develops and commercializes microwave imaging devices for diagnostic applications. Founded in 2015 as an academic spin-off of the University of Perugia and headquartered in Rivotorto di Assisi (Perugia), the company operates a wholly-owned UK subsidiary (UBT UK Division, registered 2020) in London. Its core technology exploits low-power radiofrequency signals (1-9 GHz, 1mW) and a proprietary Huygens Principle-based imaging algorithm to detect tissue dielectric inhomogeneities, producing diagnostic images without ionizing radiation. The company is structured as a Benefit Company.

The product portfolio comprises three devices: MammoWave (TRL 9, Class IIa CE-marked under MDR 2017/745 since 2024) for breast lesion detection; BrainWave (TRL 6) for brain stroke detection and classification, designed for ambulance deployment; and LungWave (TRL 4), an early-stage lung lesion detection device. MammoWave has been clinically validated in multicenter trials across Italy, Spain, Portugal, Switzerland, and Poland with 5,000+ women enrolled. Two foundational patents have been granted in Italy, EU, China, and the USA. The company holds ISO 13485 certification and has published 35+ peer-reviewed papers in journals including PLoS ONE, Scientific Reports, IEEE, and BMJ Open.

UBT generates revenue primarily through direct enterprise sales of medical imaging hardware to hospitals, clinics, and national/regional health systems. The company has no publicly disclosed revenue and no institutional venture capital or private equity investment; it has been substantially funded through European Commission grants totaling over €11 million across H2020 SME Instrument Phase 1 (2017), Phase 2 (2018, €1.4M), FETPROACT RadioSpin (2021, €3.8M), and HORIZON-MISS-2021-CANCER MammoScreen (2022, €6M+). The go-to-market relies on direct sales led by a Director of Commercial Operations Italy, supplemented by international medical conference and trade fair participation (ECR, SIRM, BIO, Arab Health, FIME, CIIE) under the EIC Overseas Trade Fairs Programme. Pricing is not publicly disclosed and follows a contact-based enterprise sales model.

Short descriptiontext

UBT Srl is an Italian medical device company that develops CE-marked microwave imaging devices—MammoWave (breast lesion detection), BrainWave (stroke classification), and LungWave (lung lesion monitoring)—using low-power radiofrequency signals instead of ionizing radiation, serving hospitals, clinics, and European health systems.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAssisi, Italy
HQ citystring
Assisi
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
microwave imaging devices, medical diagnostic equipment, breast cancer screening, stroke detection devices, radiation-free imaging
Industry1 code
PRIMARYHLAHABAF
Mammography & Breast Imaging Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
NAICS code2 codes
  • Medical Equipment and Supplies Manufacturing3391
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Imaging Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

UBT develops and commercializes medical imaging devices (MammoWave, BrainWave, LungWave) based on proprietary microwave imaging technology. Revenue generated from sales of these medical devices to hospitals and clinics.

ubt-tech.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

UBT Srl designs, develops, manufactures and commercializes patented medical imaging devices based on proprietary low-power microwave imaging technology. Its commercial products are MammoWave (breast lesion detection, TRL 9, CE-marked Class IIa under MDR 2017/745), BrainWave (stroke detection/classification, TRL 6), and LungWave (lung lesion detection, TRL 4, in development). Devices use safe radiofrequency signals (1-9 GHz, 1 mW) instead of X-rays and apply a Huygens Principle-based imaging algorithm for diagnostic image reconstruction.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Can potentially expand EU breast cancer screening to additional 98 million women in 20-49 and over 70 age groups
+2 more records
Product overview1 text field

UBT Srl develops and commercializes a portfolio of innovative medical imaging devices based on cutting-edge microwave technology. The company offers three patented products: MammoWave (TRL 9) for breast lesion detection, BrainWave (TRL 6) for stroke detection and classification, and LungWave (TRL 4) for lung lesion monitoring. All devices use safe microwave radiofrequency signals instead of ionizing radiation, exploiting dielectric property contrast for diagnostic imaging.

Product and service3 records
1MammoWave
CategoryMedical Imaging Devices — Breast Diagnostics
Description

Microwave imaging device for breast lesion detection that uses safe low-power (1 mW) radiofrequency signals in the 1-9 GHz band instead of X-rays. Employs a Huygens Principle-based imaging algorithm to generate breast images highlighting tissue dielectric inhomogeneities with high sensitivity and specificity, including in dense breasts. Examination is performed in a comfortable prone position without breast compression and has no age or frequency restrictions. CE-marked Class IIa medical device under MDR 2017/745; targets hospitals, clinics, and breast screening programs.

2BrainWave
CategoryMedical Imaging Devices — Neurology / Stroke
Description

Microwave imaging device for brain stroke detection and classification using a wave-guided configuration with two antennas operating at 1-5 GHz and 1 mW power. Differentiates hemorrhagic from ischemic stroke through dielectric property contrast analysis, enabling fast and accurate brain imaging in pre-hospital and emergency settings, including ambulance deployment. Targets emergency medical services, neurology departments, and stroke units.

3LungWave
CategoryMedical Imaging Devices — Pulmonary Diagnostics
Description

Microwave imaging device for lung lesion detection and monitoring, currently in development at TRL 4. Uses UBT's low-power microwave imaging platform to detect and monitor lung lesions without ionizing radiation.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Since 2017, UBT collaborates with LSBU's Centre for Bioengineering (BiMEC) for microwave imaging R&D and AI development. UBT sponsors Industrial PhD and Matched Funded Post-PhD positions. LSBU is a key partner in MammoScreen, RadioSpin, and ROVER EU projects.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

HORIZON-MISS-2021-CANCER-02-01 funded consortium: UBT, Toscana Life Sciences Foundation (Italy), LSBU (UK), ELAROS 24/7 Limited (UK), Servicio De Salud De Castilla La Mancha (Spain), Scuola IMT Alti Studi Lucca (Italy), EVITA (Portugal). 48-month project for MammoWave clinical validation on thousands of women.

3RadioSpin Consortium
Strategic tierCoreTypeStrategic or Co-development Partner
Description

H2020-FETPROACT funded consortium: Université de Bordeaux (coordinator), CNRS (France), INL (Portugal), Thales (France), Eurida research (Austria), UBT. 50-month project building hardware neural networks for AI integration into MammoWave.

ubt-tech.com
4ROVER Consortium
Strategic tierMinorTypeStrategic or Co-development Partner
Description

H2020 Marie Skłodowska-Curie RISE project: UBT with University of Oulu, University of Florence, LSBU, Oslo University Hospital, Elaros, Yokohama National University, University of Technology Sydney, Asian Institute of Technology, Worcester Polytechnic Institute, University of Nebraska-Lincoln for wireless body-centric systems research.

ubt-tech.com
Strategic tierCoreTypeTechnology or Integration
Description

Leader in medical imaging software for acquiring, processing and transferring medical images. Partner since 2017. Manages DICOM hospital network distribution and provides risk assessment for electromagnetic fields from medical devices.

Strategic tierCoreTypeOthers
Description

Italian certification body that awarded MammoWave CE marking and ISO 13485 certification for UBT.

7Bureau Veritas Italia
Strategic tierCoreTypeOthers
Description

Certification body that awarded MammoWave CE marking under MDR 2017/745 regulation.

ubt-tech.com
8Imago7 Foundation
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Consortium for scientific research in magnetic resonance (MR); houses the first and only 7.0 Tesla MR system in Italy. Gianluigi Tiberi coordinates the Radio Frequency laboratory at Imago7 Foundation.

ubt-tech.com
9Hospital Virgen de la Salud Toledo / Hospital Universitario de Toledo
Strategic tierCoreTypeStrategic or Co-development Partner
Description

MammoWave installed November 2019. Three clinical studies (including ongoing MammoScreen) activated at this hospital. Partner in MammoScreen project. Official start of clinical trials from November 2020.

ubt-tech.com
10Ospedale Policlinico San Martino Genova
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Three clinical studies related to MammoWave clinical validation activated at this hospital. Acting as Italian coordinator center for MammoScreen project clinical trial.

ubt-tech.com
11Azienda Ospedaliera di Perugia / Azienda Ospedaliera S. Maria della Misericordia
Strategic tierCoreTypeStrategic or Co-development Partner
Description

First MammoWave feasibility clinical trial conducted here, successfully completed 2020. Dr. Michele Duranti serves as Principal Investigator.

ubt-tech.com
12Azienda Ospedaliero Universitaria di Pisa
Strategic tierCoreTypeStrategic or Co-development Partner
Description

BrainWave feasibility clinical trial activated in 2021 under Prof. Mirco Cosottini (Director, Neurology Department).

ubt-tech.com
13Humanitas Research Hospital Milano
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial site for MammoWave breast imaging device as part of H2020-SME-Instrument-Phase2 international study.

ubt-tech.com
14MTA - Medical Trials Analysis
Strategic tierMinorTypeOthers
Description

CRO that collaborated on clinical trial protocol for MammoWave international clinical investigation (ClinicalTrials.gov NCT04253366).

ubt-tech.com
15ARPA Umbria
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership for defining dedicated protocols for electromagnetic field measurements in working and hospital environments.

ubt-tech.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major mammography equipment vendor (MAMMOMAT systems) with global commercial reach and deep hospital integration. Targets the same breast imaging procurement budgets as MammoWave.

TypeBroad incumbent
Description

Leading global mammography and breast imaging incumbent (Selenia Dimensions 3D mammography). Operates at much larger scale with established hospital relationships across the same breast screening category UBT targets.

TypeBroad incumbent
Description

Global medical imaging incumbent (MicroDose mammography). Stefano Orselli at UBT previously led Philips Healthcare Italy, illustrating the competitive overlap in breast imaging enterprise sales.

TypeEmerging player
Description

Developed SoftVue, a non-ionizing breast imaging system using ultrasound tomography. Competes in the same 'radiation-free breast imaging' category as MammoWave from a different physical modality.

TypeEmerging player
Description

Provides AI-powered breast imaging solutions (ProFound AI for DBT, mammography CAD). Relevant peer because UBT also incorporates AI classification algorithms into MammoWave for lesion detection.

TypeBroad incumbent
Description

Sells Senographe mammography systems and broader radiology portfolio. Comparable in providing imaging hardware to hospitals and competes for the same screening capital equipment budgets.

TypeEmerging player
Description

Commercializes QTscan, a non-ionizing ultrasound-based breast imaging system positioned as a radiation-free alternative to mammography — directly comparable use case to MammoWave.

TypeEmerging player
Description

Software platform for breast screening workflow, image quality, and risk assessment. Comparable in supporting population-based breast cancer screening programs — the same segment UBT targets via MammoScreen.

TypeDirect peer
Description

UK-based company developing MARIA microwave breast imaging system — the closest direct competitor to MammoWave using the same dielectric imaging approach for radiation-free breast examination.

TypeEmerging player
Description

Developed Imagio optoacoustic breast imaging system, another non-ionizing modality pursuing the same 'no radiation, dense-breast friendly' positioning in breast lesion diagnosis.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

UBT Srl

Medical Imaging Devicesubt-tech.com

UBT Srl is an Italian medical device company that develops CE-marked microwave imaging devices—MammoWave (breast lesion detection), BrainWave (stroke classification), and LungWave (lung lesion monitoring)—using low-power radiofrequency signals instead of ionizing radiation, serving hospitals, clinics, and European health systems.

What UBT Srl does

UBT Srl is an Italian medical device company that develops and commercializes microwave imaging devices for diagnostic applications. Founded in 2015 as an academic spin-off of the University of Perugia and headquartered in Rivotorto di Assisi (Perugia), the company operates a wholly-owned UK subsidiary (UBT UK Division, registered 2020) in London. Its core technology exploits low-power radiofrequency signals (1-9 GHz, 1mW) and a proprietary Huygens Principle-based imaging algorithm to detect tissue dielectric inhomogeneities, producing diagnostic images without ionizing radiation. The company is structured as a Benefit Company.

The product portfolio comprises three devices: MammoWave (TRL 9, Class IIa CE-marked under MDR 2017/745 since 2024) for breast lesion detection; BrainWave (TRL 6) for brain stroke detection and classification, designed for ambulance deployment; and LungWave (TRL 4), an early-stage lung lesion detection device. MammoWave has been clinically validated in multicenter trials across Italy, Spain, Portugal, Switzerland, and Poland with 5,000+ women enrolled. Two foundational patents have been granted in Italy, EU, China, and the USA. The company holds ISO 13485 certification and has published 35+ peer-reviewed papers in journals including PLoS ONE, Scientific Reports, IEEE, and BMJ Open.

UBT generates revenue primarily through direct enterprise sales of medical imaging hardware to hospitals, clinics, and national/regional health systems. The company has no publicly disclosed revenue and no institutional venture capital or private equity investment; it has been substantially funded through European Commission grants totaling over €11 million across H2020 SME Instrument Phase 1 (2017), Phase 2 (2018, €1.4M), FETPROACT RadioSpin (2021, €3.8M), and HORIZON-MISS-2021-CANCER MammoScreen (2022, €6M+). The go-to-market relies on direct sales led by a Director of Commercial Operations Italy, supplemented by international medical conference and trade fair participation (ECR, SIRM, BIO, Arab Health, FIME, CIIE) under the EIC Overseas Trade Fairs Programme. Pricing is not publicly disclosed and follows a contact-based enterprise sales model.

UBT Srl firmographics

Firmographics
Name
UBT Srl
Legal name
UBT Srl
Website
https://ubt-tech.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
UBT Srl is an Italian medical device company that develops CE-marked microwave imaging devices—MammoWave (breast lesion detection), BrainWave (stroke classification), and LungWave (lung lesion monitoring)—using low-power radiofrequency signals instead of ionizing radiation, serving hospitals, clinics, and European health systems.
Ownership category
akta.pro rank

UBT Srl industry classification

Industry
Product category
Medical Imaging Devices
NAICS
Medical Equipment and Supplies Manufacturing (3391), Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHABAF
Mammography & Breast Imaging Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment

Keywords

  • Microwave imaging devices
  • Medical diagnostic equipment
  • Breast cancer screening
  • Stroke detection devices
  • Radiation-free imaging

Where UBT Srl is headquartered

Location

Headquarters

HQ city
Assisi
HQ country
Italy
HQ region
Europe

Offices2 records

Markets served

UBT Srl business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Medical Device Sales: UBT develops and commercializes medical imaging devices (MammoWave, BrainWave, LungWave) based on proprietary microwave imaging technology. Revenue generated from sales of these medical devices to hospitals and clinics.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

UBT Srl product offering

Product offering

Core offering

UBT Srl designs, develops, manufactures and commercializes patented medical imaging devices based on proprietary low-power microwave imaging technology. Its commercial products are MammoWave (breast lesion detection, TRL 9, CE-marked Class IIa under MDR 2017/745), BrainWave (stroke detection/classification, TRL 6), and LungWave (lung lesion detection, TRL 4, in development). Devices use safe radiofrequency signals (1-9 GHz, 1 mW) instead of X-rays and apply a Huygens Principle-based imaging algorithm for diagnostic image reconstruction.

Product overview

UBT Srl develops and commercializes a portfolio of innovative medical imaging devices based on cutting-edge microwave technology. The company offers three patented products: MammoWave (TRL 9) for breast lesion detection, BrainWave (TRL 6) for stroke detection and classification, and LungWave (TRL 4) for lung lesion monitoring. All devices use safe microwave radiofrequency signals instead of ionizing radiation, exploiting dielectric property contrast for diagnostic imaging.

Differentiator

Problem solved

Functional benefit

Products and services

  • MammoWave Microwave imaging device for breast lesion detection that uses safe low-power (1 mW) radiofrequency signals in the 1-9 GHz band instead of X-rays. Employs a Huygens Principle-based imaging algorithm to generate breast images highlighting tissue dielectric inhomogeneities with high sensitivity and specificity, including in dense breasts. Examination is performed in a comfortable prone position without breast compression and has no age or frequency restrictions. CE-marked Class IIa medical device under MDR 2017/745; targets hospitals, clinics, and breast screening programs.
  • BrainWave Microwave imaging device for brain stroke detection and classification using a wave-guided configuration with two antennas operating at 1-5 GHz and 1 mW power. Differentiates hemorrhagic from ischemic stroke through dielectric property contrast analysis, enabling fast and accurate brain imaging in pre-hospital and emergency settings, including ambulance deployment. Targets emergency medical services, neurology departments, and stroke units.
  • LungWave Microwave imaging device for lung lesion detection and monitoring, currently in development at TRL 4. Uses UBT's low-power microwave imaging platform to detect and monitor lung lesions without ionizing radiation.

Quantifiable outcome

  • Can potentially expand EU breast cancer screening to additional 98 million women in 20-49 and over 70 age groups
  • +2 more outcomes

Companies that use UBT Srl

Customer profile

Named customers7 records

Segments2 records

Ideal customer profiles2 records

UBT Srl technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

UBT Srl partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered core and minor.

  • London South Bank University (LSBU)coreStrategic or Co-development PartnerSince 2017, UBT collaborates with LSBU's Centre for Bioengineering (BiMEC) for microwave imaging R&D and AI development. UBT sponsors Industrial PhD and Matched Funded Post-PhD positions. LSBU is a key partner in MammoScreen, RadioSpin, and ROVER EU projects.
  • MammoScreen ConsortiumcoreStrategic or Co-development PartnerHORIZON-MISS-2021-CANCER-02-01 funded consortium: UBT, Toscana Life Sciences Foundation (Italy), LSBU (UK), ELAROS 24/7 Limited (UK), Servicio De Salud De Castilla La Mancha (Spain), Scuola IMT Alti Studi Lucca (Italy), EVITA (Portugal). 48-month project for MammoWave clinical validation on thousands of women.
  • RadioSpin ConsortiumcoreStrategic or Co-development PartnerH2020-FETPROACT funded consortium: Université de Bordeaux (coordinator), CNRS (France), INL (Portugal), Thales (France), Eurida research (Austria), UBT. 50-month project building hardware neural networks for AI integration into MammoWave.
  • ROVER ConsortiumminorStrategic or Co-development PartnerH2020 Marie Skłodowska-Curie RISE project: UBT with University of Oulu, University of Florence, LSBU, Oslo University Hospital, Elaros, Yokohama National University, University of Technology Sydney, Asian Institute of Technology, Worcester Polytechnic Institute, University of Nebraska-Lincoln for wireless body-centric systems research.
  • DIGITEC SrlcoreTechnology or IntegrationLeader in medical imaging software for acquiring, processing and transferring medical images. Partner since 2017. Manages DICOM hospital network distribution and provides risk assessment for electromagnetic fields from medical devices.
  • MTIC InterCert SrlcoreOthersItalian certification body that awarded MammoWave CE marking and ISO 13485 certification for UBT.
  • Bureau Veritas ItaliacoreOthersCertification body that awarded MammoWave CE marking under MDR 2017/745 regulation.
  • Imago7 FoundationminorStrategic or Co-development PartnerConsortium for scientific research in magnetic resonance (MR); houses the first and only 7.0 Tesla MR system in Italy. Gianluigi Tiberi coordinates the Radio Frequency laboratory at Imago7 Foundation.
  • Hospital Virgen de la Salud Toledo / Hospital Universitario de ToledocoreStrategic or Co-development PartnerMammoWave installed November 2019. Three clinical studies (including ongoing MammoScreen) activated at this hospital. Partner in MammoScreen project. Official start of clinical trials from November 2020.
  • Ospedale Policlinico San Martino GenovacoreStrategic or Co-development PartnerThree clinical studies related to MammoWave clinical validation activated at this hospital. Acting as Italian coordinator center for MammoScreen project clinical trial.
  • Azienda Ospedaliera di Perugia / Azienda Ospedaliera S. Maria della MisericordiacoreStrategic or Co-development PartnerFirst MammoWave feasibility clinical trial conducted here, successfully completed 2020. Dr. Michele Duranti serves as Principal Investigator.
  • Azienda Ospedaliero Universitaria di PisacoreStrategic or Co-development PartnerBrainWave feasibility clinical trial activated in 2021 under Prof. Mirco Cosottini (Director, Neurology Department).
  • Humanitas Research Hospital MilanocoreStrategic or Co-development PartnerClinical trial site for MammoWave breast imaging device as part of H2020-SME-Instrument-Phase2 international study.
  • MTA - Medical Trials AnalysisminorOthersCRO that collaborated on clinical trial protocol for MammoWave international clinical investigation (ClinicalTrials.gov NCT04253366).
  • ARPA UmbriaminorStrategic or Co-development PartnerPartnership for defining dedicated protocols for electromagnetic field measurements in working and hospital environments.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

UBT Srl competitors and assessment

Company assessment

Broad incumbents

  • Siemens Healthineers: Major mammography equipment vendor (MAMMOMAT systems) with global commercial reach and deep hospital integration. Targets the same breast imaging procurement budgets as MammoWave.
  • Hologic: Leading global mammography and breast imaging incumbent (Selenia Dimensions 3D mammography). Operates at much larger scale with established hospital relationships across the same breast screening category UBT targets.
  • Philips Healthcare: Global medical imaging incumbent (MicroDose mammography). Stefano Orselli at UBT previously led Philips Healthcare Italy, illustrating the competitive overlap in breast imaging enterprise sales.
  • GE Healthcare: Sells Senographe mammography systems and broader radiology portfolio. Comparable in providing imaging hardware to hospitals and competes for the same screening capital equipment budgets.

Emerging players

  • Delphinus Medical Technologies: Developed SoftVue, a non-ionizing breast imaging system using ultrasound tomography. Competes in the same 'radiation-free breast imaging' category as MammoWave from a different physical modality.
  • iCAD: Provides AI-powered breast imaging solutions (ProFound AI for DBT, mammography CAD). Relevant peer because UBT also incorporates AI classification algorithms into MammoWave for lesion detection.
  • QT Ultrasound: Commercializes QTscan, a non-ionizing ultrasound-based breast imaging system positioned as a radiation-free alternative to mammography — directly comparable use case to MammoWave.
  • Volpara Health: Software platform for breast screening workflow, image quality, and risk assessment. Comparable in supporting population-based breast cancer screening programs — the same segment UBT targets via MammoScreen.
  • Seno Medical Instruments: Developed Imagio optoacoustic breast imaging system, another non-ionizing modality pursuing the same 'no radiation, dense-breast friendly' positioning in breast lesion diagnosis.

Direct peers

  • Micrima: UK-based company developing MARIA microwave breast imaging system — the closest direct competitor to MammoWave using the same dielectric imaging approach for radiation-free breast examination.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

UBT Srl social profiles

Digital presence

UBT Srl compliance and trust

Trust signal

Compliance2 records

UBT Srl financial estimates

Financial estimate

Revenue estimate

Valuation estimate

UBT Srl leadership team

Management profile

Number of profiles

Profiles17 records

UBT Srl subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

UBT Srl funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

UBT Srl M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about UBT Srl

What does UBT Srl do?

UBT Srl designs, develops, manufactures and commercializes patented medical imaging devices based on proprietary low-power microwave imaging technology. Its commercial products are MammoWave (breast lesion detection, TRL 9, CE-marked Class IIa under MDR 2017/745), BrainWave (stroke detection/classification, TRL 6), and LungWave (lung lesion detection, TRL 4, in development). Devices use safe radiofrequency signals (1-9 GHz, 1 mW) instead of X-rays and apply a Huygens Principle-based imaging algorithm for diagnostic image reconstruction.

Is UBT Srl a public or private company?

UBT Srl is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was UBT Srl founded?

UBT Srl was founded in 2015. It employs 11 to 50 people.

Where is UBT Srl based?

UBT Srl is headquartered in Assisi, Italy, in the Europe region.

How does UBT Srl make money?

One revenue line is on record: medical Device Sales.

Who are UBT Srl's main competitors?

Broad incumbents on record are Siemens Healthineers, Hologic, Philips Healthcare and GE Healthcare. Emerging players are Delphinus Medical Technologies, iCAD, QT Ultrasound, Volpara Health and Seno Medical Instruments. Micrima is listed as a direct peer.

Does UBT Srl have an API?

No public API is recorded for UBT Srl.

What industry is UBT Srl in?

UBT Srl's product category is Medical Imaging Devices. Its primary akta.pro industry code is HLAHABAF, Mammography & Breast Imaging Systems. Its NAICS code is 3391 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales